Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Completed 9Recruiting 4Terminated 3Active not recruiting 3Unknown 2Withdrawn 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER_GOV 1OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4Thoracic 1Gynecologic 1

Conditions

Melanoma 50Carcinoma, Non-Small-Cell Lung 39Carcinoma, Renal Cell 28Carcinoma, Hepatocellular 18Neoplasm Metastasis 16Neoplasms 15Colorectal Neoplasms 15Stomach Neoplasms 13Lung Neoplasms 13Adenocarcinoma Of Esophagus 11Squamous Cell Carcinoma of Head and Neck 10Carcinoma, Transitional Cell 8Brain Neoplasms 8Hodgkin Disease 7Skin Neoplasms 6Sarcoma 6Kidney Neoplasms 6Esophageal Neoplasms 6Triple Negative Breast Neoplasms 5Prostatic Neoplasms 5Pancreatic Neoplasms 5Clear-cell metastatic renal cell carcinoma 5Carcinoma, Merkel Cell 5Uveal Melanoma 4Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Recurrence 4Neuroendocrine Tumors 4Nasopharyngeal Carcinoma 4Mesothelioma 4

Interventions

tebentafusp 4Nivolumab 4Magnetic Resonance Spectroscopy 3Cyclophosphamide 3pembrolizumab 2fludarabine phosphate 2fludarabine 2cemiplimab 2Specimen Handling 2Ipilimumab 2Interleukin-2 2sargramostim 1quisinostat 1olaparib 1lifileucel 1binimetinib 1aldesleukin 1aflibercept 1Valproic Acid 1Spinal Puncture 1Protein Kinase C 1Melatonin 1Interleukin-13 1Hematologic Tests 1Granulocyte-Macrophage Colony-Stimulating Factor 1Fluorodeoxyglucose F18 1Exercise 1Crizotinib 1Carmustine 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Uveal Melanoma × Nivolumab × Clear all
NCT03686124 2026-05-13

ACTengine

Immatics US, Inc.

Phase 1/2 Recruiting
375 enrolled
DermatologicGynecologic

Uveal Melanoma, Melanoma, Neoplasms, Ovarian Neoplasms, Recurrence

NCT03025256 2026-05-05

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

M.D. Anderson Cancer Center

Phase 1 Recruiting
75 enrolled
DermatologicThoracic

Uveal Melanoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Meningeal Neoplasms, Nevus

NCT06581406 2026-04-02

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Replimune, Inc.

Phase 2/3 Recruiting
280 enrolled
Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT06519266 2024-11-25

SCANDIUM-III

Vastra Gotaland Region

Phase 3 Recruiting
40 enrolled
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡